Cellectar Biosciences, Inc.
Business
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing cancer drugs using its proprietary phospholipid ether drug conjugate (PDC) platform for targeted delivery. Its lead programs include iopofosine I-131 (a beta-emitting radioconjugate in Phase 2/pivotal studies for Waldenstrom macroglobulinemia and multiple myeloma), CLR 125 (an Auger-emitting iodine-125 radioconjugate in Phase 1b for triple-negative breast cancer), and CLR 225 (an alpha-emitting actinium-225 radioconjugate in preclinical development for solid tumors). The company develops PDCs through research collaborations and internal programs, targeting both hematologic and solid cancers in orphan-designated indications.
Summary from 10-K filed 2026-03-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 11 | 26 | 27 | 19 | 18 | |
| General and administrative | 11 | 26 | 12 | 10 | 7 | |
| Total operating expenses | 23 | 52 | 39 | 29 | 24 | |
| LOSS FROM OPERATIONS | −23 | −52 | −39 | −29 | −24 | |
| Warrant issuance expense | — | −8 | −470,000 | — | — | |
| Gain on valuation of warrants | 753,707 | 14 | −4 | — | — | |
| Interest income | 435,100 | 1 | 387,147 | 152,519 | 2,284 | |
| Total other income (expense), net | 1 | 7 | −4 | 152,519 | 8,918 | |
| LOSS BEFORE INCOME TAXES | −22 | −45 | −43 | −29 | −24 | |
| INCOME TAX PROVISION (BENEFIT) | — | 66,000 | −60,000 | −60,000 | — | |
| NET LOSS | −22 | −45 | −43 | −29 | −24 | |
| NET LOSS PER SHARE - BASIC (In dollars per share) | −8.35 | −36.52 | −3.5 | −4.05 | −4.35 | |
| NET LOSS PER SHARE - DILUTED (In dollars per share) | −8.35 | −41.89 | −3.5 | −4.05 | −4.35 | |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC (In shares) | 3 | 1 | 12 | 7 | 6 | |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED (In shares) | 3 | 1 | 12 | 7 | 6 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 13 | 23 | 10 | 20 | 36 | |
| Prepaid expenses and other current assets | 842,432 | 961,665 | 888,225 | 663,243 | 867,485 | |
| Total current assets | 14 | 24 | 10 | 21 | 37 | |
| Property, plant & equipment, net | 549,405 | 757,121 | 1 | 418,641 | 344,491 | |
| Operating lease right-of-use asset | 360,671 | 436,874 | 502,283 | 560,334 | 204,644 | |
| Other long-term assets | 29,780 | 29,780 | 29,780 | 6,214 | 6,214 | |
| TOTAL ASSETS | 15 | 25 | 12 | 22 | 37 | |
| Accounts payable and accrued liabilities | 4 | 8 | 9 | 5 | 4 | |
| Warrant liability | 226,000 | 2 | 16 | — | — | |
| Lease liability, current | 100,189 | 84,417 | 58,979 | 50,847 | 135,449 | |
| Total current liabilities | 5 | 9 | 25 | 6 | 4 | |
| Lease liability, net of current portion | 309,397 | 409,586 | 494,003 | 552,981 | 166,292 | |
| TOTAL LIABILITIES | 5 | 10 | 26 | 6 | 4 | |
| COMMITMENTS AND CONTINGENCIES (Note 10) | — | — | — | — | — | |
| Common stock, $0.00001 par value; 170,000,000 shares authorized; 4,240,129 and 1,535,996 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 42 | 15 | 207 | 94 | 61 | |
| Additional paid-in capital | 277 | 261 | 183 | 194 | 183 | |
| Accumulated deficit | −269 | −247 | −203 | −179 | −151 | |
| Total stockholders' equity | 9 | 14 | −15 | 8 | 33 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 15 | 25 | 12 | 22 | 37 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 214,000 | 292,000 | 192,000 | 148,000 | 150,000 | |
| Stock-based compensation | 2 | 4 | 2 | 1 | 1 | |
| Loss on disposal of assets | — | 145,726 | — | 3,386 | 2,937 | |
| Warrant issuance expense | — | 8 | 470,000 | — | — | |
| Change in operating lease right-of-use asset | 76,202 | 65,409 | 58,051 | — | — | |
| Prepaid expenses and other assets | 119,233 | −73,440 | −173,548 | 204,242 | −93,053 | |
| Accounts payable and accrued liabilities | −3 | −2 | 4 | 2 | 411,717 | |
| Lease liability | −84,417 | −58,979 | −50,846 | −144,035 | −119,903 | |
| Cash used in operating activities | −23 | −48 | −32 | −25 | −23 | |
| Purchases of property, plant & equipment | −5,880 | −104,195 | −864,038 | −225,971 | −141,361 | |
| Cash used in investing activities | −5,880 | −104,195 | −864,038 | −225,971 | −141,361 | |
| Proceeds from exercise of warrants and new warrants, net of issuance costs | 7 | 61 | 789,642 | — | 1 | |
| Proceeds from issuance of common stock, pre-funded warrants and common warrants, net of issuance costs | 6 | — | — | — | — | |
| Cash provided by financing activities | 13 | 61 | 23 | 10 | 1 | |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | −10 | 14 | −10 | −16 | −21 | |
| Conversion of preferred stock to common stock | — | 68 | 13 | — | — | |
| Settlement of warrants to equity | 738,325 | 13 | 3 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cellectar Biosciences, Inc.'s CIK number?
Cellectar Biosciences, Inc.'s SEC CIK number is 0001279704 (1279704). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cellectar Biosciences, Inc.'s SEC filings?
All of Cellectar Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Cellectar Biosciences, Inc. last report earnings?
Cellectar Biosciences, Inc. (CLRB) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-060693). This is Cellectar Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Cellectar Biosciences, Inc.'s most recent earnings 8-K?
Cellectar Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001104659-26-060693. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Cellectar Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →